Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Accumulated Expenses (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Accumulated Expenses data on record, last reported at $6.4 million in Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 227.79% year-over-year to $6.4 million; the TTM value through Sep 2025 reached $6.4 million, up 227.79%, while the annual FY2024 figure was $72.1 million, 91.97% up from the prior year.
  • Accumulated Expenses reached $6.4 million in Q3 2025 per COLL's latest filing, up from $6.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $72.1 million in Q4 2024 and bottomed at $467000.0 in Q3 2022.
  • Average Accumulated Expenses over 5 years is $12.6 million, with a median of $2.6 million recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 4376.95% in 2022, then tumbled 93.28% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $807000.0 in 2021, then surged by 4376.95% to $36.1 million in 2022, then increased by 3.99% to $37.6 million in 2023, then soared by 91.97% to $72.1 million in 2024, then tumbled by 91.17% to $6.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $6.4 million in Q3 2025, $6.1 million in Q2 2025, and $1.4 million in Q1 2025.